ReviewCurrent allergy and asthma reports2026
Updates in Pediatric Drug Allergy.
Review in Current allergy and asthma reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review is aimed to update clinical allergists on recent international changes in classification, diagnosis, and management of pediatric drug allergy with a focus on antibiotics and NSAID allergy labels. RECENT
findingsGuidelines have begun to standardize nomenclature, classification, and diagnostic approaches. In a progressive update, there is now a standard amoxicillin dose for direct provocation challenges, a defined severity scale for immediate reactors, and decreased threshold to drug provocation challenges for patients with serum sickness like reactions. Within antibiotic allergy label investigation, skin testing is being bypassed in favor of direct oral challenges performed in a single day without the use of extended challenges. Continued investigation of the index reaction phenotypes, safety of drug challenges, and diagnostic certainty of in vitro studies will continue to advance the field of pediatric drug allergy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.